Sarcosine and Decreased Risk for Prostate Cancer in Schizophrenia
The Open Clinical Chemistry Journal · 2009
DOI: 10.2174/1874241600902010022 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Open Clinical Chemistry Journal, 2009. Verfasst von Kenji Hashimoto. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Schizophrenia is a disabling major mental illness that affects approximately 1% of the world population, characterized by positive symptoms (e.g., unusual thoughts or perceptions, including hallucinations, delusions, thought disorder, and disorders of movement) and negative symptoms (e.g., loss or a decrease in the ability to initiate plans, speak, express emotion, or find pleasure in everyday life), and cognitive deficits (e.g., problems with attention, certain types of memory, and the executive functions). For almost 100 years, there has been speculation that patients with schizophrenia have lower cancer risks than the general population. In recent years, population-based studies have become available, allowing an analysis of the data by specific types of cancer and schizophrenia. Mortensen [1] reported that the incidence of prostate cancer in the male patients with schizophrenia was significantly lower than that of the general Danish population. A recent population-based, nested, casecontrolled study demonstrated a 40.7% lower risk of prostate cancer in male patients with schizophrenia [2], consistent with that of previous studies [1,3], which have shown an approximately 50% lower risk. In contrast, patients with bipolar disorder had similar cancer risks as people without either mental health condition after adjustment for the potential confounding factors (e.g., socioeconomic status, smoking, obesity, comorbidity, and concurrent use of other medications) [2], indicating the specificity for schizophrenia. It has been suggested that genetic factors, antipsychotic medications, and lifestyle differences may be associated with the lower risk of prostate cancer [4,5] although the precise etiology underlying the lower risk of prostate cancer in schizophrenia were unclear. In the 2009 February issue of Nature, Sreekumar et al. [6] reported that sarcosine (N-methylglycine) was identified as a biomarker that was highly increased during prostate cancer progression to metastasis and can be detected non-invasively in urine. Sarcosine is generated by the enzymatic transfer of a methyl group from S-adenosylmethionine to glycine (Fig. 1), and this reaction is catalyzed by the enzyme glycine N-methyltransferase (GNMT) (Fig. 1), which is expressed in prostate at high levels
Zitieren
APA
Hashimoto, K. (2009). Sarcosine and Decreased Risk for Prostate Cancer in Schizophrenia. The Open Clinical Chemistry Journal. https://doi.org/10.2174/1874241600902010022
Vancouver
Hashimoto K. Sarcosine and Decreased Risk for Prostate Cancer in Schizophrenia. The Open Clinical Chemistry Journal. 2009. doi:10.2174/1874241600902010022
BibTeX
@article{Hashimoto2009,
author = {Hashimoto, Kenji},
title = {Sarcosine and Decreased Risk for Prostate Cancer in Schizophrenia},
journal = {The Open Clinical Chemistry Journal},
year = {2009},
doi = {10.2174/1874241600902010022}
}
EUVIMED